Clin2
NCT06887426Possibly a fitNot yet recruiting

Cladribine tablets as a way to stop MS therapy

Multiple SclerosisRelapsing Remitting Multiple SclerosisSecondary Progressive Multiple Sclerosis

Treatments studied

Part of Brain & nervous system, Immune system & allergy clinical trials.

This study tests whether cladribine tablets can help people with stable, long-standing RRMS safely stop their current disease-modifying therapy. It may be an option if your MS has been quiet for years and you want to consider a treatment break.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
450 people
Ages
45 years and older
Study type
Observational

Who can take part

  • You are 45 years old or older.
  • You have relapsing-remitting MS (RRMS) for at least 10 years.
  • Your MS has been stable (no relapses or new lesions) for at least 5 years while on a disease-modifying therapy.
  • Your disability level (EDSS score) is between 0 and 6.0.
  • You do not have a progressive form of MS.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT05961644Recruiting· Phase 2/Phase 3
Cladribine vs placebo for non-active progressive multiple sclerosis

This trial tests whether cladribine (vs an inactive placebo pill) can slow disability worsening in people with a non-active, progressive form of multiple sclerosis. It may help by reducing the immune activity that can drive ongoing nerve damage, even without recent relapses.

Warsaw, Masovian Voivodeship
NCT07517185Not yet recruiting· Phase 2
Early aggressive treatment for relapsing multiple sclerosis

This trial tests whether treating relapsing multiple sclerosis (RRMS) aggressively and early with a specific medication can slow disease progression. You may qualify if you were recently diagnosed, have had recent disease activity, and are willing to take a strong immunosuppressive drug with regular MRI monitoring.

Falun
NCT05285891Recruiting· Phase 4
Stopping ocrelizumab in early relapsing multiple sclerosis

This study looks at whether people with early relapsing multiple sclerosis can safely stop ocrelizumab. Researchers will compare health and MRI findings over time to see if stopping helps or increases relapse risk.

New Haven, Connecticut
NCT04676204Enrolling by invitation
How MS treatment “burden” may affect taking medicines

This study looks at whether the amount of MS treatment-related “burden” in the mouth and body affects how well people stick to their disease-modifying therapy. It may help doctors understand which patients are more likely to have trouble following treatment after switching or starting certain MS medicines.

Melbourne, Victoria
NCT07477639Recruiting· Phase 1/Phase 2
Testing TRX319 for worsening multiple sclerosis

This trial tests a new treatment called TRX319 for people with progressive multiple sclerosis (MS) that has been getting worse. The study wants to see if this treatment can help slow down disability progression.

Kansas City, Kansas
NCT07020715Not yet recruiting· Phase 2
Vitamin D immune cell therapy for progressive MS

This trial tests a new treatment using your own immune cells trained with vitamin D to calm MS. It is for people with progressive MS who are not on other MS drugs.

Edegem

Hear when a new Multiple sclerosis trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.